Fuller & Thaler Asset Management Inc. Increases Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Fuller & Thaler Asset Management Inc. raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 7.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 887,852 shares of the biopharmaceutical company's stock after acquiring an additional 64,308 shares during the quarter. Fuller & Thaler Asset Management Inc. owned about 0.70% of Halozyme Therapeutics worth $42,448,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth $29,000. CBIZ Investment Advisory Services LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth $29,000. Smartleaf Asset Management LLC increased its holdings in shares of Halozyme Therapeutics by 29.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter worth $69,000. Finally, Parkside Financial Bank & Trust increased its stake in Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 322 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of research analyst reports. Benchmark reissued a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Piper Sandler increased their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. HC Wainwright restated a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Friday. Finally, JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a report on Monday, April 21st. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $62.89.

Halozyme Therapeutics Stock Up 1.7 %

HALO stock traded up $1.01 during midday trading on Tuesday, hitting $61.58. The stock had a trading volume of 142,278 shares, compared to its average volume of 1,431,556. The firm has a market cap of $7.61 billion, a price-to-earnings ratio of 17.91, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The business has a 50-day moving average of $60.56 and a two-hundred day moving average of $55.20. Halozyme Therapeutics, Inc. has a 52-week low of $37.97 and a 52-week high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the company's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director now owns 28,611 shares in the company, valued at approximately $1,727,246.07. The trade was a 13.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 26,697 shares of company stock valued at $1,558,052 over the last 90 days. 2.40% of the stock is owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.